Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-996-5252
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Kala Pharmaceuticals (NASDAQ:KALA) Frequently Asked Questions
What is Kala Pharmaceuticals' stock symbol?
Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA."
How were Kala Pharmaceuticals' earnings last quarter?
Kala Pharmaceuticals Inc (NASDAQ:KALA) issued its quarterly earnings data on Thursday, November, 8th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by $0.01. View Kala Pharmaceuticals' Earnings History.
When is Kala Pharmaceuticals' next earnings date?
What price target have analysts set for KALA?
5 brokerages have issued 12 month price targets for Kala Pharmaceuticals' shares. Their predictions range from $15.00 to $51.00. On average, they anticipate Kala Pharmaceuticals' stock price to reach $23.60 in the next year. This suggests a possible upside of 196.9% from the stock's current price. View Analyst Price Targets for Kala Pharmaceuticals.
What is the consensus analysts' recommendation for Kala Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kala Pharmaceuticals.
What are Wall Street analysts saying about Kala Pharmaceuticals stock?
Here are some recent quotes from research analysts about Kala Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Kala Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles technology. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts and the female reproductive systems. Kala Pharmaceuticals, Inc. is based in Waltham, United States. " (3/26/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a market value of the firm at $495M, which includes a discounted cash flow-based asset value of $570M for INVELTYS (100% probability of success) and KPI-121 0.25% (65% probability of success), with a 15% discount rate and 0.5% terminal growth rate, excluding $75M debt." (12/27/2018)
Has Kala Pharmaceuticals been receiving favorable news coverage?
News coverage about KALA stock has trended somewhat negative on Tuesday, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kala Pharmaceuticals earned a daily sentiment score of -1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Are investors shorting Kala Pharmaceuticals?
Kala Pharmaceuticals saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 1,400,258 shares, an increase of 40.4% from the February 15th total of 997,467 shares. Based on an average trading volume of 361,919 shares, the days-to-cover ratio is currently 3.9 days. Currently, 5.6% of the shares of the company are short sold. View Kala Pharmaceuticals' Current Options Chain.
Who are some of Kala Pharmaceuticals' key competitors?
Some companies that are related to Kala Pharmaceuticals include CannTrust (CNTTF), Ra Pharmaceuticals (RARX), Inflarx (IFRX), Clementia Pharmaceuticals (CMTA), Tricida (TCDA), Homology Medicines (FIXX), Amphastar Pharmaceuticals (AMPH), Retrophin (RTRX), Vanda Pharmaceuticals (VNDA), MacroGenics (MGNX), Deciphera Pharmaceuticals (DCPH), Dicerna Pharmaceuticals (DRNA), Alder Biopharmaceuticals (ALDR), Kiniksa Pharmaceuticals (KNSA) and Radius Health (RDUS).
What other stocks do shareholders of Kala Pharmaceuticals own?
Who are Kala Pharmaceuticals' key executives?
Kala Pharmaceuticals' management team includes the folowing people:
- Mr. Mark T. Iwicki, Chairman, Pres & CEO (Age 53)
- Mr. Todd Bazemore, Chief Operating Officer (Age 49)
- Dr. Kim Brazzell, Chief Medical Officer (Age 66)
- Dr. Justin Hanes Ph.D., Founder & Chair of the Scientific Advisory Board
- Ms. Mary Reumuth CPA, CFO & Treasurer (Age 44)
When did Kala Pharmaceuticals IPO?
(KALA) raised $90 million in an initial public offering (IPO) on Thursday, July 20th 2017. The company issued 6,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.
Who are Kala Pharmaceuticals' major shareholders?
Kala Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include RA Capital Management LLC (13.43%), BlackRock Inc. (4.22%), Athyrium Capital Management LP (3.95%), Sofinnova Investments Inc. (1.32%), Broadfin Capital LLC (1.00%) and Dimensional Fund Advisors LP (0.76%). Company insiders that own Kala Pharmaceuticals stock include Associates LLC Cdk, Gregory Grunberg, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Institutional Ownership Trends for Kala Pharmaceuticals.
Which major investors are selling Kala Pharmaceuticals stock?
Which major investors are buying Kala Pharmaceuticals stock?
KALA stock was acquired by a variety of institutional investors in the last quarter, including RA Capital Management LLC, Athyrium Capital Management LP, Sofinnova Investments Inc., BlackRock Inc., Fosun International Ltd, Pura Vida Investments LLC, Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. Company insiders that have bought Kala Pharmaceuticals stock in the last two years include Associates LLC Cdk, Gregory Grunberg, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Rajeev M Shah. View Insider Buying and Selling for Kala Pharmaceuticals.
How do I buy shares of Kala Pharmaceuticals?
Shares of KALA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kala Pharmaceuticals' stock price today?
One share of KALA stock can currently be purchased for approximately $7.95.
How big of a company is Kala Pharmaceuticals?
Kala Pharmaceuticals has a market capitalization of $269.37 million. The company earns $-66,740,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.
What is Kala Pharmaceuticals' official website?
How can I contact Kala Pharmaceuticals?
Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. The company can be reached via phone at 781-996-5252 or via email at [email protected]
MarketBeat Community Rating for Kala Pharmaceuticals (NASDAQ KALA)
MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALA will underperform the S&P 500 over the long term. You may vote once every thirty days.
